VIVES Partners has invested €84 million in Nuclidium AG to enhance the clinical development of its copper-based radiopharmaceuticals, marking VIVES's first foray into the nuclear medicine sector.

Target Information

Nuclidium AG is a clinical-stage biotechnology company based in Switzerland, specializing in the development of next-generation radiopharmaceuticals utilizing copper-based isotopes. With a focus on innovations in theranostics, Nuclidium aims to enhance diagnostic and therapeutic efficacy for various cancer types, including metastatic prostate cancer, neuroendocrine tumors, and breast cancer. The company's proprietary platform leverages copper-61 for diagnostic purposes and copper-67 for therapeutic applications, positioning it at the forefront of modern medical advancements in oncology.

Nuclidium's operations extend across Switzerland and Germany, where they emphasize innovative chemistry, clinical expertise, and strategic production capabilities. Their mission revolves around addressing significant unmet medical needs in oncology and women's health, with a commitment to providing scalable, accessible, and clinically superior theranostic solutions for patients globally.

Industry Overview

The radiopharmaceutical industry, particularly in Switzerland, is witnessing robust growth driven by an increasing demand for targeted therapies in cancer treatment. With advancements in medical technology, radiopharmaceuticals have become vita